Core Viewpoint - Century Therapeutics, Inc. is advancing its preclinical cell therapy programs targeting autoimmune diseases and cancer, with a live event scheduled to discuss these developments [1][2]. Group 1: Company Overview - Century Therapeutics is a clinical-stage biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancers [4]. - The company aims to create off-the-shelf cell therapies to enhance patient access and improve treatment outcomes in autoimmune disease and cancer care [4]. Group 2: Upcoming Event Details - A live fireside chat will take place on April 22, 2025, at 10:00 a.m. EDT, where management will present details and data on prioritized preclinical programs [1]. - The event will cover investigational cell therapies including CNTY-308, a CD19-targeted CAR-iT therapy, and CNTY-341, a dual-targeted CAR-iT therapy, as well as a solid tumor CAR iT program [2]. - The discussion will highlight the proprietary immune evasion technology, Allo-Evasion™ 5.0, which aims to enable comprehensive evasion of various immune responses [2]. Group 3: Accessing Information - The live event can be accessed via the Investors page on Century's website, with a replay available for at least 30 days post-event [3].